Affimed's Unit AbCheck Signs Research Partnership With Pierre Fabre Pharma

(RTTNews) - Affimed N.V. (AFMD), a clinical-stage biopharmaceutical company developing targeted cancer immunotherapies, Wednesday announced that its unit AbCheck s.r.o and Pierre Fabre Pharmaceuticals have expanded their ongoing collaboration into a strategic research partnership in the field of human antibody discovery and optimization.

AbCheck is recognized for its expertise in human antibody discovery and optimization throughout the US and Europe. Pierre Fabre, the third largest French pharmaceutical company, has a long-standing commitment to oncology and immunology.

Under the expanded agreement, AbCheck will use its proprietary human antibody discovery and optimization platform technologies, AbSieve and AbAccel, to deliver antibodies against two or more targets provided by Pierre Fabre per year over a period of three years.

This period can be extended to up to five years. Pierre Fabre has secured full rights to all antibodies selected in exchange for discovery fees and milestone payments to AbCheck. Additional deal terms as well as financial details were not disclosed.